HIMS vs. NTRA, GH, RDNT, OPCH, SHC, BTSG, WGS, CON, SGRY, and PRVA
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Guardant Health (GH), RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), GeneDx (WGS), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry.
Hims & Hers Health vs. Its Competitors
Natera (NASDAQ:NTRA) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.
Hims & Hers Health has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Hims & Hers Health has a net margin of 9.63% compared to Natera's net margin of -12.89%. Hims & Hers Health's return on equity of 26.26% beat Natera's return on equity.
Natera has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.
In the previous week, Hims & Hers Health had 56 more articles in the media than Natera. MarketBeat recorded 84 mentions for Hims & Hers Health and 28 mentions for Natera. Natera's average media sentiment score of 1.12 beat Hims & Hers Health's score of 0.23 indicating that Natera is being referred to more favorably in the media.
Natera presently has a consensus price target of $193.19, indicating a potential upside of 19.29%. Hims & Hers Health has a consensus price target of $38.92, indicating a potential downside of 11.16%. Given Natera's stronger consensus rating and higher possible upside, equities research analysts clearly believe Natera is more favorable than Hims & Hers Health.
99.9% of Natera shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 5.6% of Natera shares are held by insiders. Comparatively, 13.7% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Hims & Hers Health beats Natera on 9 of the 17 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
This page (NYSE:HIMS) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access